Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A comprehensive clinical guide to delayed-onset and rare adverse events linked to Praluent (alirocumab), covering PCSK9 inhibitor trial data, FAERS reports, post-market surveillance, and monitoring protocols.
Read clinical reviewDoes stopping Praluent cause a withdrawal or rebound effect? A physician-reviewed guide to alirocumab discontinuation, LDL rebound data, adverse events, and safe stopping protocols.
Read clinical reviewA detailed breakdown of alirocumab (Praluent) adverse event rates from ODYSSEY trials, FAERS data, and post-market literature, with direct comparisons across doses and populations.
Read clinical reviewA clinical review of Praluent (alirocumab) side effects, including rare, serious, and potentially permanent adverse events drawn from key trials, the FDA label, and post-market surveillance.
Read clinical reviewA clinician-reviewed guide to the rare but serious adverse events linked to Praluent (alirocumab), including PCSK9-inhibitor class effects, neurocognitive signals, hepatic risk, and immunogenicity data from ODYSSEY OUTCOMES and the FDA label.
Read clinical reviewA clinical breakdown of alirocumab (Praluent) adverse events by severity grade and patient phenotype, drawing on ODYSSEY trial data, FDA labeling, and FAERS reports.
Read clinical review